Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E15.93 EPS (ttm)5.53 Insider Own0.10% Shs Outstand714.15M Perf Week-0.35%
Market Cap62.95B Forward P/E7.02 EPS next Y12.56 Insider Trans-3.18% Shs Float701.19M Perf Month-0.56%
Income4.05B PEG0.89 EPS next Q2.43 Inst Own77.30% Short Float2.73% Perf Quarter34.42%
Sales15.28B P/S4.12 EPS this Y5.90% Inst Trans1.89% Short Ratio1.66 Perf Half Y0.88%
Book/sh8.81 P/B10.01 EPS next Y17.38% ROA11.80% Target Price97.66 Perf Year-0.18%
Cash/sh8.46 P/C10.42 EPS next 5Y17.96% ROE82.50% 52W Range58.59 - 95.30 Perf YTD37.54%
Dividend- P/FCF13.00 EPS past 5Y26.80% ROI16.70% 52W High-7.50% Beta1.71
Dividend %- Quick Ratio2.10 Sales past 5Y18.70% Gross Margin96.20% 52W Low50.45% ATR1.69
Employees8852 Current Ratio2.20 Sales Q/Q15.90% Oper. Margin34.00% RSI (14)51.83 Volatility1.50% 1.77%
OptionableYes Debt/Eq3.29 EPS Q/Q-2.20% Profit Margin26.50% Rel Volume0.64 Prev Close89.63
ShortableYes LT Debt/Eq3.21 EarningsMay 02 BMO Payout0.00% Avg Volume11.51M Price88.15
Recom2.40 SMA200.86% SMA500.35% SMA2006.81% Volume7,309,989 Change-1.65%
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Mar-24-19 02:00PM  3 Bargain Stocks You Can Buy Today Motley Fool
01:00PM  Is It Safe to Buy Biogen Stock Right Now? InvestorPlace
Mar-21-19 10:03AM  Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition Zacks
07:30AM  Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.
Mar-20-19 04:16PM  Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key Investor's Business Daily
11:24AM  Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Zacks
08:55AM  Buy These 5 ROE Stocks as Stock Market Euphoria Continues Zacks
08:32AM  The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene Zacks
Mar-19-19 09:33PM  Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle? Motley Fool
06:18PM  [$$] If This Is Failure, Show Me Success The Wall Street Journal
05:53PM  Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia Zacks
02:26PM  Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse Zacks
02:17PM  Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.
01:14PM  Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat
11:57AM  PhaseBio Stock Up on Positive Data From PB2452 Phase I Study Zacks
11:51AM  Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients Zacks
11:24AM  Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer
10:48AM  Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk
09:53AM  Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers
09:52AM  Are Americans More Confident in 2019? 5 Top Picks Zacks
09:45AM  Bristol-Myers Squibb and Starboard Value square off over Celgene deal American City Business Journals
Mar-18-19 06:44PM  Bristol-Myers & Pfizer Release Phase IV Data on Eliquis Zacks
05:45PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
09:30AM  Is Celgene (CELG) Outperforming Other Medical Stocks This Year? Zacks
08:06AM  AstraZeneca Up This Year on New Drugs & Pipeline Progress Zacks
07:25AM  Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study Zacks
06:23AM  Bear of the Day: Gilead Sciences (GILD) Zacks
Mar-15-19 04:04PM  Roche Gets Approval for Label Expansion of MabThera in Europe Zacks
03:36PM  Top Ranked Value Stocks to Buy for March 14th Zacks
02:00PM  Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail? Motley Fool
12:04PM  Top Ranked Value Stocks to Buy for March 15th Zacks
11:38AM  AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag Zacks
11:25AM  PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y Zacks
05:05AM  J&J Seeks Approval for Darzalex in Expanded Patient Group Zacks
Mar-14-19 05:15PM  Washington Health Care Facilities Auth -- Moody's upgrades Fred Hutchinson Cancer Research Center (WA) to A2 from A3; outlook stable Moody's
04:24PM  Key Celgene Issue That Could 'Unnerve' Bristol Takeover Was Just Tossed Investor's Business Daily
11:20AM  Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why Zacks
11:13AM  Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up Zacks
09:32AM  U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug Reuters
09:09AM  U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid Reuters
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019
04:37PM  Celgenes Positive Drug Data Bolsters Bristol-Myers Deal, Analyst Says
04:17PM  Does This Celgene-Roche Approval Sweeten The Pot For Bristol? Investor's Business Daily
12:50PM  Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma Zacks
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
09:30AM  CELG vs. VRTX: Which Stock Is the Better Value Option? Zacks
09:11AM featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals Zacks
08:54AM  Top Ranked Value Stocks to Buy for March 11th Zacks
Mar-12-19 04:59PM  How This Looming Patent Battle Could Challenge Bristol-Celgene Deal Investor's Business Daily
04:30PM  Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer Business Wire
03:22PM  Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Zacks
10:07AM  Celgene (CELG) Submits Application for MS Drug in Europe Zacks
09:59AM  Alnylam Files Application for Hypertension Candidate in UK Zacks
09:55AM  Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer Zacks
09:42AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
06:06AM  3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade Motley Fool
Mar-11-19 06:14PM  Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source Reuters
05:45PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
10:35AM  AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study Zacks
07:30AM  Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis Business Wire
02:28AM  Here's Why bluebird bio Gained 16.3% in February Motley Fool
Mar-09-19 06:00AM  3 Top Biotech Stocks to Buy in March Motley Fool
Mar-08-19 11:04AM  Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat Zacks
10:10AM  Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up Zacks
10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
12:49AM  [$$] Why old-school asset managers are copying the activists Financial Times
Mar-07-19 10:20PM  NanoString Technologies Inc (NSTG) Q4 2018 Earnings Conference Call Transcript Motley Fool
11:58AM  I Like the Long Side of Bristol-Myers Squibb
09:06AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
07:56AM  Top Ranked Value Stocks to Buy for March 7th Zacks
Mar-06-19 08:22PM  Bristol-Myers CEO: Celgene merger will yield 6 products in 24 months CNBC Videos
05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
04:09PM  Bristol Slides As Drug Giant Defends Its Looming Celgene Takeover Investor's Business Daily
12:20PM  Bristol-Myers defends Celgene bet as investor criticism grows Reuters
10:26AM  Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More Zacks
10:21AM featured highlights include: Best Buy, Celgene, General Motors, Facebook and CBRE Zacks
10:14AM  Bristol-Myers says Celgene deal is 'best path' as investor opposition mounts Reuters
08:11AM  Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance CNBC
07:06AM  Celgene buy best path forward, Bristol-Myers says Reuters
Mar-05-19 10:02PM  [$$] Bristol-Myers Squibb defends Celgene takeover as best path Financial Times
09:22AM  Why Geron Skyrocketed 27% in February Motley Fool
08:32AM  5 ROE Stocks to Profit as Trade Talks Enter Decisive Phase Zacks
07:30AM  U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis Business Wire
07:15AM  3 Best Biotech Bargain Stocks on the Market Right Now Motley Fool
Mar-04-19 11:38PM  Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks Zacks
07:23PM  [$$] Celgene Odds Are in Investors Favor The Wall Street Journal
05:15PM  Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion Zacks
01:24PM  Bristol-Myers Squibb's $74B deal for Celgene criticized, called risky American City Business Journals
11:26AM  Watch CNBC's exclusive interview with Jim Woolery CNBC Videos
07:12AM  S&P 500 Closes Above 2,800 After Nearly 4 Months: 5 Picks Zacks
Mar-01-19 04:52PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
04:25PM  Bristol Investors Face Tough Road In Quashing Celgene Deal: Analyst Investor's Business Daily
04:02PM  The Bristol-MyersSquibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
02:20PM  Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up Zacks
02:18PM  Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales Zacks
02:03PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks
10:17AM  Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up Zacks
09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
09:33AM  Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM